ESMO 2020 | No benefit of adjuvant palbociclib in HR+, HER2- breast cancer patients

Erica Mayer provides a top-line overview of the phase 3 PALLAS trial evaluating the addition of palbociclib to adjuvant endocrine therapy in patients with early-stage, hormone receptor-positive, HER2-negative breast cancer (2:14).